Stage III Non-Small Cell Lung Cancer Treated Without Concurrent Chemotherapy: What Is the Optimal Radiation Dose?

Abstract

Based on the preliminary results of RTOG 0617, there may not be an overall survival (OS) benefit for dose escalation beyond 60 Gy in patients with stage III non-small cell lung cancer (NSCLC) treated with concurrent chemotherapy and radiation therapy (CRT). However, the optimal radiation dose in the absence of concurrent chemotherapy remains unclear. We hypothesized that there may be a benefit for higher radiation doses in the absence of concurrent chemotherapy.